Elecsys CEA Assay 11731629160Recalls & reported problems
Roche Diagnostics GmbH · Class 2
Data updated Oct 18, 2026 from official FDA records · Editorial policy
- Adverse event reports
- 1
- Deaths reported
- 0
- Injuries reported
- 0
- Recalls naming it
- 0
Summary
The FDA's MAUDE database contains 1 adverse event report that list this exact device (DI 04015630938766), received between Aug 27, 2018 and Aug 27, 2018 — classified as 1 malfunction.
The most frequently reported specific device problem is “Low Test Results” (1 report).
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.
Most reported problems
Device problems
- Low Test Results1
Patient problems
- No Consequences Or Impact To Patient1
Recent adverse event reports
The 1 most recent of 1 reports, in the reporter's own words as published by the FDA.
MalfunctionAug 27, 2018Low Test Results; Low Test Results
THE CUSTOMER COMPLAINED OF DISCREPANT ELECSYS CEA ASSAY RESULTS FOR 3 PATIENT SAMPLES ON A COBAS E 411 IMMUNOASSAY ANALYZER SERIAL NUMBER (B)(4). FOR PATIENT 1 THE INITIAL CEA RESULT WAS 36.2 NG/ML AND THE REPEAT RESULT WAS 25.6 NG/ML ON THE E 411. THE SAMPLE WAS SENT TO A DIFFERENT LABORATORY. THE CEA RESULT WAS 63.5 NG/ML ON THE ABBOTT ARCHITECT INSTRUMENT AND WAS REPORTED OUTSIDE OF THE LABORATORY. ON (B)(6) 2018, THE CUSTOMER CHANGED THE REAGENT PACK AND RECALIBRATED. THE SAMPLE WAS REPEATED AND THE CEA RESULTS WERE 50.9 NG/ML AND 50.7 NG/ML. FOR PATIENT 2 ON (B)(6) 2018, THE INITIAL CEA RESULT WAS 90 NG/ML AND THE REPEAT RESULT WAS 70 NG/ML ON THE E 411. THE CEA RESULT WAS 200 NG/ML IN A DIFFERENT LABORATORY WITH THE ABBOTT ARCHITECT. FOR PATIENT 3 ON (B)(6) 2018, THE INITIAL CEA RESULT WAS 89 NG/ML AND THE REPEAT RESULT WAS 90 NG/ML ON THE E 411. THE CEA RESULT WAS 400 NG/ML IN A DIFFERENT LABORATORY WITH THE ABBOTT ARCHITECT. NO ERRONEOUS RESULTS WERE REPORTED OUTSIDE OF THE LABORATORY. THERE WAS NO ADVERSE EVENT. THE FIELD SERVICE ENGINEER(FSE) RAN A PERFORMANCE TEST THAT FAILED. THE FSE PERFORMED AN ADJUSTMENT AND AN INITIAL CELL BLANK. THE CALIBRATION AND QC WERE ACCEPTAB
Patient problems: No Consequences Or Impact To Patient
MAUDE report 7818983 ↗
Other SYSTEM, TEST, CARCINOEMBRYONIC ANTIGEN devices
- ADVIA Centaur® CEA 10309977Siemens Healthcare Diagnostics Inc. · SYSTEM, TEST, CARCINOEMBRYONIC ANTIGEN14 reports
- ARCHITECT 07K68-27Abbott Ireland Diagnostics · SYSTEM, TEST, CARCINOEMBRYONIC ANTIGEN13 reports
- Elecsys CEA 07027079190Roche Diagnostics GmbH · SYSTEM, TEST, CARCINOEMBRYONIC ANTIGEN13 reports
- Atellica IM CEA 10995523Siemens Healthcare Diagnostics Inc. · SYSTEM, TEST, CARCINOEMBRYONIC ANTIGEN11 reports
- ADVIA Centaur® CEA 10309978Siemens Healthcare Diagnostics Inc. · SYSTEM, TEST, CARCINOEMBRYONIC ANTIGEN10 reports
- IMMULITE® 2000 Systems CEA 10380995Siemens Healthcare Diagnostics Products Ltd · SYSTEM, TEST, CARCINOEMBRYONIC ANTIGEN9 reports
- Elecsys Anti-CCP 07251670190Roche Diagnostics GmbH · SYSTEM, TEST, CARCINOEMBRYONIC ANTIGEN8 reports
- ARCHITECT 07K68-35Abbott Ireland Diagnostics · SYSTEM, TEST, CARCINOEMBRYONIC ANTIGEN8 reports
Sources and updates
- Device record: FDA GUDID, file dated Oct 13, 2026 · View this device in AccessGUDID ↗
- Adverse event reports: FDA MAUDE, file dated Oct 14, 2026 · each report above links to its original FDA record
- Recalls: FDA Medical Device Recalls, file dated Oct 16, 2026
- Page last rebuilt: Oct 18, 2026. Data downloaded through openFDA, which notes it is not validated for clinical or regulatory use.
How reports and recalls are matched · Editorial policy · Report an error on this page